[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"header_nav":3,"site_settings":49,"news-cats":177,"footer-nav":178,"news-related-strategic-partnership":196},[4,13,19,25,31,37,43],{"collectionId":5,"collectionName":6,"id":7,"label":8,"label_en":9,"position":10,"sort":11,"to":12},"pbc_3079337391","navigation","8hvz111cztwtf6i","关于我们","About Us","header",1,"\u002Fabout",{"collectionId":5,"collectionName":6,"id":14,"label":15,"label_en":16,"position":10,"sort":17,"to":18},"9d57585v6wd81ob","硅基芯片","Silicon-Based Biochips",2,"\u002Fchip",{"collectionId":5,"collectionName":6,"id":20,"label":21,"label_en":22,"position":10,"sort":23,"to":24},"mq9ap452ye9u2h1","人工智能","Artificial Intelligence",3,"\u002Fai",{"collectionId":5,"collectionName":6,"id":26,"label":27,"label_en":28,"position":10,"sort":29,"to":30},"384105938294iqe","业务合作","Business Partnerships",4,"\u002Fbusiness",{"collectionId":5,"collectionName":6,"id":32,"label":33,"label_en":34,"position":10,"sort":35,"to":36},"gurwh855qx5x6z4","新闻洞察","News",5,"\u002Fnews",{"collectionId":5,"collectionName":6,"id":38,"label":39,"label_en":40,"position":10,"sort":41,"to":42},"55ii5pqdkj1kdm3","加入我们","Join Us",6,"\u002Fjoin",{"collectionId":5,"collectionName":6,"id":44,"label":45,"label_en":46,"position":10,"sort":47,"to":48},"xn76c1083o2wu6o","联系我们","Contact Us",7,"\u002Fcontact",[50,57,61,65,70,75,80,85,89,93,98,102,107,111,115,119,124,128,133,138,143,148,153,158,162,167,172],{"collectionId":51,"collectionName":52,"id":53,"key":54,"rich":55,"rich_en":55,"value":56,"value_en":55},"pbc_3940974","site_settings","d6b65u865t21sv6","contact_phone_400","","+86 0756  885 8456",{"collectionId":51,"collectionName":52,"id":58,"key":59,"rich":55,"rich_en":55,"value":60,"value_en":55},"t63em90l5t0057n","contact_phone_office","+86 0755 3360 5888",{"collectionId":51,"collectionName":52,"id":62,"key":63,"rich":55,"rich_en":55,"value":64,"value_en":55},"iq8p641sog8x9l1","contact_hours","9:00-18:00",{"collectionId":51,"collectionName":52,"id":66,"key":67,"rich":55,"rich_en":55,"value":68,"value_en":69},"96j6s7t0fp409nl","contact_address_1","珠海市横琴粤澳深度合作区","Hengqin Guangdong-Macao In-Depth Cooperation Zone, Zhuhai, China",{"collectionId":51,"collectionName":52,"id":71,"key":72,"rich":55,"rich_en":55,"value":73,"value_en":74},"r6i9s5b90ymlf8x","contact_address_2","深圳市南山区、龙华区","Nanshan & Longhua Districts, Shenzhen, China",{"collectionId":51,"collectionName":52,"id":76,"key":77,"rich":55,"rich_en":55,"value":78,"value_en":79},"f4c7i35vq97ewp2","contact_address_3","广州市黄埔区","Huangpu District, Guangzhou, China",{"collectionId":51,"collectionName":52,"id":81,"key":82,"rich":55,"rich_en":55,"value":83,"value_en":84},"ko6t44bi839hodo","about_intro_body","iCarbonX由王俊博士于2015年创立，总部位于中国深圳。\r\n\r\n一家开创性的数字生命“独角兽”企业，利用人工智能和基于硅的生物芯片技术开展全球药物研发与精准诊断，推动基因组学、蛋白质组学及数字健康行业的创新发展。\r\n\r\n其核心使命是将“数字生活”确立为推动下一代医疗健康技术发展的核心引擎。","Founded by Dr. Jun Wang in 2015 and headquartered in Shenzhen, China, iCarbonX is a pioneering Digital Life unicorn company.\r\n\r\nLeveraging artificial intelligence and silicon-based biochip technologies, iCarbonX is advancing global drug discovery and precision diagnostics, driving innovation across genomics, proteomics, and digital health.\r\n\r\nThe company’s mission is to establish Digital Life as a core engine for the next generation of healthcare technologies, enabling a new paradigm for understanding, predicting, and managing human health.",{"collectionId":51,"collectionName":52,"id":86,"key":87,"rich":55,"rich_en":55,"value":88,"value_en":55},"7mzu6m751f2gi9s","footer_qr_wechat","\u002Fimages\u002Fqr-wechat.png",{"collectionId":51,"collectionName":52,"id":90,"key":91,"rich":55,"rich_en":55,"value":92,"value_en":55},"0mj7k314c63r901","footer_qr_service","\u002Fimages\u002Fqr-service.png",{"collectionId":51,"collectionName":52,"id":94,"key":95,"rich":55,"rich_en":55,"value":96,"value_en":97},"17s4u72w2r5xx61","footer_copyright","碳云智能 版权所有","2026 iCarbonX. All Rights Reserved.",{"collectionId":51,"collectionName":52,"id":99,"key":100,"rich":55,"rich_en":55,"value":101,"value_en":55},"1r73785526oyb5g","footer_icp","粤ICP备XXXXXXXX号",{"collectionId":51,"collectionName":52,"id":103,"key":104,"rich":55,"rich_en":55,"value":105,"value_en":106},"m18017xwyg619nz","footer_bottom_links","免责声明|隐私政策|合作留言","Legal Notice | Privacy Policy | Partnership Inquiry",{"collectionId":51,"collectionName":52,"id":108,"key":109,"rich":55,"rich_en":55,"value":110,"value_en":55},"dacxba346f9gbkb","company_name","碳云智能",{"collectionId":51,"collectionName":52,"id":112,"key":113,"rich":55,"rich_en":55,"value":114,"value_en":55},"f56760493weie55","company_name_en","iCarbonX",{"collectionId":51,"collectionName":52,"id":116,"key":117,"rich":55,"rich_en":55,"value":118,"value_en":55},"8rb3vp7rrvmk47x","contact_map_image","\u002Fimages\u002Fcontact-map.jpg",{"collectionId":51,"collectionName":52,"id":120,"key":121,"rich":55,"rich_en":55,"value":122,"value_en":123},"9l39447nvqg0h82","home_hero_title","碳云生命科学","iCarbonX Life Sciences",{"collectionId":51,"collectionName":52,"id":125,"key":126,"rich":55,"rich_en":55,"value":127,"value_en":9},"8z84pp8eh36l23i","about_intro_title","公司简介",{"collectionId":51,"collectionName":52,"id":129,"key":130,"rich":55,"rich_en":55,"value":131,"value_en":132},"7p72xq4e1hz3x70","breadcrumb_home","首页","Home",{"collectionId":51,"collectionName":52,"id":134,"key":135,"rich":55,"rich_en":55,"value":136,"value_en":137},"5i7p416ohiwsi20","contact_hero_subtitle","让科技创新驱动生命科学与医疗健康的发展","Advancing Life Sciences and Healthcare Through Scientific Innovation.",{"collectionId":51,"collectionName":52,"id":139,"key":140,"rich":55,"rich_en":55,"value":141,"value_en":142},"y42721r8l05o24e","contact_section_info_title","联系方式","Contact Information",{"collectionId":51,"collectionName":52,"id":144,"key":145,"rich":55,"rich_en":55,"value":146,"value_en":147},"w2k2150u9rfvgs9","contact_section_form_title","合作留言","Partnership Inquiry",{"collectionId":51,"collectionName":52,"id":149,"key":150,"rich":55,"rich_en":55,"value":151,"value_en":152},"547lm3f26e80hrk","contact_label_phone","联系电话：","Phone",{"collectionId":51,"collectionName":52,"id":154,"key":155,"rich":55,"rich_en":55,"value":156,"value_en":157},"pv1j69xs0p60178","contact_label_address","公司地址：","Address",{"collectionId":51,"collectionName":52,"id":159,"key":160,"rich":55,"rich_en":55,"value":161,"value_en":46},"6f6u830ngs8ad17","contact_seo_title","联系我们 — 碳云智能",{"collectionId":51,"collectionName":52,"id":163,"key":164,"rich":55,"rich_en":55,"value":165,"value_en":166},"op5n44iu558vm23","contact_seo_description","联系碳云智能，获取更多产品与服务信息。","Contact iCarbonX to learn more about our products and services.",{"collectionId":51,"collectionName":52,"id":168,"key":169,"rich":170,"rich_en":171,"value":55,"value_en":55},"20walg0187po22p","disclaimer","\u003Cp>法律声明\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>感谢您访问本公司网站（以下简称“本网站”）。为保障您与本公司的权益，请在使用本网站前仔细阅读以下法律声明。当您进入或使用本网站，即视为您已阅读、理解并同意遵守本声明的内容及所有相关适用法律。如您不同意以下任何条款，请立即停止使用本网站。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>一、知识产权\u003C\u002Fp>\r\n\u003Cp>本网站所载全部内容，包括但不限于文字、图片、音视频、图像、声音、文件、设计、版式及网站架构，均受《中华人民共和国著作权法》《中华人民共和国商标法》及其他相关知识产权法律保护。除法律另有规定或经本公司事先书面授权外，任何人不得以任何形式（包括但不限于复制、改编、编辑、传播、公开传输、展示或其他使用方式）使用本网站内容。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>二、免责声明\u003C\u002Fp>\r\n\u003Cp>本网站所提供的信息仅供参考。本公司不对信息的准确性、及时性、完整性或适用性作出任何明示或默示保证，并保留随时修改、更新或删除网站内容的权利。\u003C\u002Fp>\r\n\u003Cp>使用者因浏览、使用或引用本网站内容而造成的任何损害（包括直接、间接、附带或衍生损失），本公司概不承担任何责任。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>三、第三方链接\u003C\u002Fp>\r\n\u003Cp>为方便网络用户，本网站可能提供指向第三方网站的链接。使用者对相关网站内容的使用应自行评估并承担风险，本公司不对其内容的准确性、合法性、安全性或因使用产生的任何损害承担责任。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>四、使用限制\u003C\u002Fp>\r\n\u003Cp>使用者不得以任何方式从事以下行为：\u003C\u002Fp>\r\n\u003Cp>未经授权擅自进入本网站的服务器、系统或相关设备；\u003C\u002Fp>\r\n\u003Cp>散布病毒、恶意程序或从事其他危害网站安全的行为；\u003C\u002Fp>\r\n\u003Cp>以任何可能损害本公司合法权益或影响网站正常运营的方式使用本网站；\u003C\u002Fp>\r\n\u003Cp>恶意篡改或歪曲本网站提供的资料与素材，若因此导致与原始内容不符并造成损害，使用者须自行承担相应的民事或刑事法律责任；\u003C\u002Fp>\r\n\u003Cp>本声明不赋予使用者代表本网站发表意见、建议或视为本公司对相关衍生内容予以认可。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>五、隐私政策\u003C\u002Fp>\r\n\u003Cp>本公司高度重视您的个人信息保护。当您使用本网站或提供个人信息时，我们将依据《中华人民共和国个人信息保护法》及本公司《隐私政策》进行处理与保护。建议您详细阅读本网站所载隐私政策，以了解我们收集、使用、存储及保护个人信息的方式。若您不同意本政策，请勿向本公司提供任何个人信息。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>六、适用法律与管辖\u003C\u002Fp>\r\n\u003Cp>本法律声明的解释与适用，以及因使用本网站所引起的争议，均适用中华人民共和国法律，并由本公司所在地人民法院管辖。\u003C\u002Fp>","\u003Ch1 data-section-id=\"sq8q4f\" data-start=\"0\" data-end=\"14\">Legal Notice\u003C\u002Fh1>\r\n\u003Cp data-start=\"16\" data-end=\"519\">Thank you for visiting the official website of the Company (the \"Website\"). To protect both your interests and those of the Company, please read the following Legal Notice carefully before accessing or using this Website. By accessing or using this Website, you acknowledge that you have read, understood, and agreed to be bound by this Legal Notice and all applicable laws and regulations. If you do not agree with any part of this Legal Notice, please discontinue your use of this Website immediately.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"3a4rq9\" data-start=\"521\" data-end=\"548\">1. Intellectual Property\u003C\u002Fh2>\r\n\u003Cp data-start=\"550\" data-end=\"906\">All content available on this Website, including but not limited to text, images, graphics, audio, video, documents, designs, layouts, and the overall website structure, is protected by the Copyright Law of the People's Republic of China, the Trademark Law of the People's Republic of China, and other applicable intellectual property laws and regulations.\u003C\u002Fp>\r\n\u003Cp data-start=\"908\" data-end=\"1156\">Unless otherwise permitted by law or expressly authorized in writing by the Company, no person or organization may reproduce, modify, edit, distribute, publicly transmit, display, publish, or otherwise use any content from this Website in any form.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"ib2d2y\" data-start=\"1158\" data-end=\"1174\">2. Disclaimer\u003C\u002Fh2>\r\n\u003Cp data-start=\"1176\" data-end=\"1532\">The information provided on this Website is for general informational purposes only. The Company makes no express or implied warranties regarding the accuracy, timeliness, completeness, reliability, or suitability of any information contained on this Website and reserves the right to modify, update, or remove any content at any time without prior notice.\u003C\u002Fp>\r\n\u003Cp data-start=\"1534\" data-end=\"1744\">The Company shall not be liable for any direct, indirect, incidental, consequential, or other damages arising from or related to the access to, use of, or reliance upon the information provided on this Website.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"hmhkff\" data-start=\"1746\" data-end=\"1769\">3. Third-Party Links\u003C\u002Fh2>\r\n\u003Cp data-start=\"1771\" data-end=\"2106\">For your convenience, this Website may contain links to third-party websites. Your access to and use of such websites are entirely at your own risk. The Company assumes no responsibility for the accuracy, legality, security, privacy practices, or content of any third-party website, nor for any loss or damage resulting from their use.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"xb7ely\" data-start=\"2108\" data-end=\"2128\">4. Acceptable Use\u003C\u002Fh2>\r\n\u003Cp data-start=\"2130\" data-end=\"2188\">Users shall not engage in any of the following activities:\u003C\u002Fp>\r\n\u003Cul data-start=\"2190\" data-end=\"2959\">\r\n\u003Cli data-section-id=\"18rb8j\" data-start=\"2190\" data-end=\"2282\">Accessing the Website's servers, systems, or related infrastructure without authorization;\u003C\u002Fli>\r\n\u003Cli data-section-id=\"1g0nz1c\" data-start=\"2283\" data-end=\"2412\">Transmitting viruses, malicious code, or engaging in any activity that may compromise the security or integrity of the Website;\u003C\u002Fli>\r\n\u003Cli data-section-id=\"kgdrh2\" data-start=\"2413\" data-end=\"2556\">Using the Website in any manner that may infringe upon the Company's legitimate rights or interfere with the normal operation of the Website;\u003C\u002Fli>\r\n\u003Cli data-section-id=\"dsi9py\" data-start=\"2557\" data-end=\"2752\">Altering, distorting, or misrepresenting any content or materials obtained from this Website. Users shall bear full civil or criminal liability for any consequences resulting from such actions;\u003C\u002Fli>\r\n\u003Cli data-section-id=\"w4hxm1\" data-start=\"2753\" data-end=\"2959\">Representing themselves as speaking on behalf of the Website or the Company, or implying that the Company endorses any opinions, recommendations, or derivative content without prior written authorization.\u003C\u002Fli>\r\n\u003C\u002Ful>\r\n\u003Ch2 data-section-id=\"1ajrc9k\" data-start=\"2961\" data-end=\"2974\">5. Privacy\u003C\u002Fh2>\r\n\u003Cp data-start=\"2976\" data-end=\"3268\">The Company is committed to protecting your personal information. Any personal information collected through your use of this Website will be processed and protected in accordance with the Personal Information Protection Law of the People's Republic of China and the Company's Privacy Policy.\u003C\u002Fp>\r\n\u003Cp data-start=\"3270\" data-end=\"3520\">We encourage you to review our Privacy Policy to understand how we collect, use, store, and safeguard your personal information. If you do not agree with our Privacy Policy, please refrain from providing any personal information through this Website.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"38rmmm\" data-start=\"3522\" data-end=\"3558\">6. Governing Law and Jurisdiction\u003C\u002Fh2>\r\n\u003Cp data-start=\"3560\" data-end=\"3675\">This Legal Notice shall be governed by and construed in accordance with the laws of the People's Republic of China.\u003C\u002Fp>\r\n\u003Cp data-start=\"3677\" data-end=\"3866\" data-is-last-node=\"\" data-is-only-node=\"\">Any dispute arising out of or relating to the use of this Website or this Legal Notice shall be submitted to the competent People's Court with jurisdiction over the location of the Company.\u003C\u002Fp>",{"collectionId":51,"collectionName":52,"id":173,"key":174,"rich":175,"rich_en":176,"value":55,"value_en":55},"m6a3t8g6b8d22d6","privacy_policy","\u003Cp>隐私政策\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>为使您在使用本网站提供的各项服务与信息时更加安心，本公司特此说明本网站的隐私政策，旨在保障您的个人隐私权益。请您仔细阅读以下内容：\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>一、适用范围\u003C\u002Fp>\r\n\u003Cp>本网站为提供安全、可用与完整的信息服务，并符合相关法律法规的要求，制定本政策。以下政策适用于您在使用本网站所提供的各类服务及活动时，涉及的个人信息收集、处理、使用与保护之相关做法，但不适用于本网站所链接的其他网站。凡经由本网站链接进入的其他网站，适用各该网站的隐私政策，与本网站无关，本网站亦不承担任何相关责任。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>二、个人信息的收集、处理及使用方式\u003C\u002Fp>\r\n\u003Cp>当您访问本网站所涉及的个人信息，其收集、处理及使用将依照《中华人民共和国个人信息保护法》及本公司业务相关规定办理，以充分保障您的隐私权。但为向您提供更完善的个性化服务，本网站会记录使用者的 IP 地址、上网时间、Cookie 以及在网站内所浏览的页面等信息\u003Cspan style=\"font-family: 等线;\">，并仅对整体用户行为进行汇总分析，用于统计网站访问量、点击率等数据性评估，不涉及单个用户的身份识别。\u003C\u002Fspan>\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>三、信息保护\u003C\u002Fp>\r\n\u003Cp>本网站主机均配置有防火墙、防病毒系统等相关信息安全设备及必要的安全防护措施，以确保数据在传输过程中不被第三方非法获取。但请您理解，互联网并非绝对安全环境，本公司无法保证数据传输的绝对安全。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>四、外部网站链接\u003C\u002Fp>\r\n\u003Cp>本网站页面可能提供其他网站的链接，您可通过本网站进入其他网站。但该等网站不适用本网站的隐私政策，您须自行查阅并遵守该网站的隐私政策。本网站对第三方网站的内容或隐私政策不承担任何责任。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>五、信息提供的限制\u003C\u002Fp>\r\n\u003Cp>除下列情形外，本网站绝不会向第三方提供您的个人信息：\u003C\u002Fp>\r\n\u003Cp>配合司法机关合法调查；\u003C\u002Fp>\r\n\u003Cp>配合相关主管机关依职权需要的调查或使用；\u003C\u002Fp>\r\n\u003Cp>为维护及改进本网站服务，进行内部管理或业务运营所必需。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>六、设备信息的使用\u003C\u002Fp>\r\n\u003Cp>本网站会收集您使用的设备（如电脑、手机、平板电脑等）的信息，包括 Cookie 信息、移动设备信息、浏览器版本、操作系统类型，以及通过 Google Analytics 等网站分析工具所收集的相关信息。本网站可能识别您的设备，并基于您的使用情况为您提供个性化体验与内容。\u003C\u002Fp>\r\n\u003Cp>您也可以通过浏览器设置拒绝或限制部分数据收集。但请注意，如拒绝或禁用 Cookie，某些服务或功能可能无法正常使用。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>七、隐私政策的修订\u003C\u002Fp>\r\n\u003Cp>本网站将不时修订隐私与个人信息保护政策，并在政策有重大变更时，于网站上公布修订内容，以落实对您隐私权的保障。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>八、联系方式\u003C\u002Fp>\r\n\u003Cp>如您对本网站的隐私政策有任何疑问或建议，欢迎随时与我们联系，我们将竭诚为您提供帮助。\u003C\u002Fp>","\u003Ch1 data-section-id=\"1dp7kw\" data-start=\"0\" data-end=\"16\">Privacy Policy\u003C\u002Fh1>\r\n\u003Cp data-start=\"18\" data-end=\"230\">To help you use the services and information provided on this website with confidence, the Company hereby sets out this Privacy Policy to protect your personal privacy rights. Please read the following carefully.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"k18ylf\" data-start=\"232\" data-end=\"258\">1. Scope of Application\u003C\u002Fh2>\r\n\u003Cp data-start=\"260\" data-end=\"434\">This Policy has been formulated to ensure that this website provides secure, accessible, and complete information services in compliance with applicable laws and regulations.\u003C\u002Fp>\r\n\u003Cp data-start=\"436\" data-end=\"885\">It applies to the collection, processing, use, and protection of personal information in connection with the services and activities provided through this website. It does not apply to third-party websites linked from this website. Any third-party website accessed through such links is governed by its own privacy policy. This website assumes no responsibility for the content, privacy practices, or related activities of such third-party websites.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"1dnm8hd\" data-start=\"887\" data-end=\"948\">2. Collection, Processing, and Use of Personal Information\u003C\u002Fh2>\r\n\u003Cp data-start=\"950\" data-end=\"1266\">Any collection, processing, and use of personal information arising from your access to this website will be conducted in accordance with the Personal Information Protection Law of the People’s Republic of China and the Company’s relevant internal policies, with due regard for the protection of your privacy rights.\u003C\u002Fp>\r\n\u003Cp data-start=\"1268\" data-end=\"1648\">To provide more complete and personalized services, this website may record information such as your IP address, access time, cookies, and the pages you visit. Such information will only be used in aggregated form to analyze overall user behavior, including website traffic, click-through rates, and other statistical indicators, and will not be used to identify individual users.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"1twmmv6\" data-start=\"1650\" data-end=\"1676\">3. Information Security\u003C\u002Fh2>\r\n\u003Cp data-start=\"1678\" data-end=\"1909\">The servers used by this website are protected by firewalls, antivirus systems, and other necessary information security equipment and safeguards designed to help prevent unauthorized third-party access to data during transmission.\u003C\u002Fp>\r\n\u003Cp data-start=\"1911\" data-end=\"2088\">However, please understand that the internet is not an entirely secure environment, and the Company cannot guarantee the absolute security of data transmitted over the internet.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"68ks82\" data-start=\"2090\" data-end=\"2122\">4. Links to External Websites\u003C\u002Fh2>\r\n\u003Cp data-start=\"2124\" data-end=\"2400\">This website may contain links to other websites. You may access such websites through links provided on this website. However, those websites are not governed by this Privacy Policy. You should review and comply with the privacy policies of the relevant third-party websites.\u003C\u002Fp>\r\n\u003Cp data-start=\"2402\" data-end=\"2505\">This website assumes no responsibility for the content or privacy practices of any third-party website.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"13d5n8r\" data-start=\"2507\" data-end=\"2558\">5. Restrictions on the Disclosure of Information\u003C\u002Fh2>\r\n\u003Cp data-start=\"2560\" data-end=\"2675\">Except in the following circumstances, this website will not disclose your personal information to any third party:\u003C\u002Fp>\r\n\u003Cul data-start=\"2677\" data-end=\"3014\">\r\n\u003Cli data-section-id=\"zrxmtw\" data-start=\"2677\" data-end=\"2753\">To cooperate with lawful investigations conducted by judicial authorities;\u003C\u002Fli>\r\n\u003Cli data-section-id=\"jdzy49\" data-start=\"2754\" data-end=\"2884\">To cooperate with investigations or requests made by competent regulatory authorities in accordance with their statutory powers;\u003C\u002Fli>\r\n\u003Cli data-section-id=\"1yqscld\" data-start=\"2885\" data-end=\"3014\">Where necessary for the internal management, business operations, maintenance, or improvement of this website and its services.\u003C\u002Fli>\r\n\u003C\u002Ful>\r\n\u003Ch2 data-section-id=\"1952gv7\" data-start=\"3016\" data-end=\"3047\">6. Use of Device Information\u003C\u002Fh2>\r\n\u003Cp data-start=\"3049\" data-end=\"3354\">This website may collect information about the devices you use, including computers, mobile phones, and tablets. Such information may include cookie data, mobile device information, browser version, operating system type, and information collected through website analytics tools such as Google Analytics.\u003C\u002Fp>\r\n\u003Cp data-start=\"3356\" data-end=\"3519\">This website may recognize your device and use information about your interactions with the website to provide a more personalized experience and relevant content.\u003C\u002Fp>\r\n\u003Cp data-start=\"3521\" data-end=\"3733\">You may refuse or limit certain types of data collection through your browser settings. However, please note that disabling or rejecting cookies may prevent certain services or features from functioning properly.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"1vl95v6\" data-start=\"3735\" data-end=\"3771\">7. Changes to this Privacy Policy\u003C\u002Fh2>\r\n\u003Cp data-start=\"3773\" data-end=\"4036\">This website may revise this Privacy Policy and its personal information protection practices from time to time. Where material changes are made, the revised content will be published on this website to help ensure the continued protection of your privacy rights.\u003C\u002Fp>\r\n\u003Ch2 data-section-id=\"1cga21h\" data-start=\"4038\" data-end=\"4054\">8. Contact Us\u003C\u002Fh2>\r\n\u003Cp data-start=\"4056\" data-end=\"4197\" data-is-last-node=\"\" data-is-only-node=\"\">Should you have any questions or suggestions regarding this Privacy Policy, please feel free to contact us. We will be pleased to assist you.\u003C\u002Fp>",[],[179,182,184,188,190,194],{"collectionId":5,"collectionName":6,"id":180,"label":8,"label_en":9,"position":181,"sort":11,"to":12},"89zd5122404ke2i","footer",{"collectionId":5,"collectionName":6,"id":183,"label":33,"label_en":34,"position":181,"sort":17,"to":36},"8n89f7o0s1t321p",{"collectionId":5,"collectionName":6,"id":185,"label":186,"label_en":187,"position":181,"sort":23,"to":18},"7573jk0xg279qc6","技术与平台","Technology & Platforms",{"collectionId":5,"collectionName":6,"id":189,"label":39,"label_en":40,"position":181,"sort":29,"to":42},"e4q2e4q39xb76mx",{"collectionId":5,"collectionName":6,"id":191,"label":192,"label_en":193,"position":181,"sort":35,"to":30},"tdotlb5tn821i16","产品与解决方案","Products & Solutions",{"collectionId":5,"collectionName":6,"id":195,"label":45,"label_en":46,"position":181,"sort":41,"to":48},"03wra0k3z082q32",[197,213,224,235,246],{"category":198,"collectionId":199,"collectionName":200,"content":201,"content_en":202,"cover":203,"id":204,"published":205,"published_at":206,"slug":207,"summary":208,"summary_en":209,"title":210,"title_en":211,"views":212},"company","pbc_4287850865","articles","\u003Cp>近日，碳云智能申报的\u003Cstrong>\"衰老及健康-疾病转化过程的高分辨率蛋白质互作组的图谱绘制及超早期风险预警体系研究\"\u003C\u002Fstrong>项目，成功入选2025年度横琴粤澳深度合作区产业核心和关键技术攻关项目。\u003C\u002Fp>\r\n\u003Cp>该项目聚焦衰老及疾病转化过程中的蛋白质互作网络，旨在绘制高分辨率互作图谱并构建超早期风险预警体系，是精准医疗与数字生命交叉领域的前沿探索。此次入选，标志着公司自主研发的\"\u003Cstrong>全球独家新一代硅基原位合成生物聚体芯片\u003C\u002Fstrong>\"及其\"\u003Cstrong>百元级、微量血、万项联检\u003C\u002Fstrong>\"应用的创新性、可行性和必要性获得权威认可。\u003C\u002Fp>\r\n\u003Cp>横琴粤澳深度合作区产业核心和关键技术攻关项目是聚焦国家战略需求、破解\"卡脖子\"技术难题的重大产业科技专项，经形式审查、专家评审、集中答辩、现场考察等多轮竞争性遴选，\u003Cstrong>2025年度仅16个项目脱颖而出\u003C\u002Fstrong>，评审严格、含金量高。\u003C\u002Fp>\r\n\u003Cp>长期以来，人体在衰老及健康向疾病转化过程中的蛋白质互作网络，因缺乏\u003Cstrong>高通量、高灵敏度\u003C\u002Fstrong>的检测手段，一直处于动态观测的技术盲区。现有检测手段面临“通量低、成本高、用样多、鉴定深度不足、核心技术依赖进口”等挑战，仅能对已发病例提供有限诊断工具，无法实现低门槛高效率绘制高分辨率分子图谱，很难对衰老及健康-疾病这一转化过程进行超早期风险预警建模。\u003C\u002Fp>\r\n\u003Cp>碳云智能秉持数字生命愿景，通过半导体工艺与生物检测的跨界融合，成功构建了以\u003Cstrong>“碳\u003C\u002Fstrong>\u003Cstrong>云芯思™”高通量硅基芯片\u003C\u002Fstrong>和\u003Cstrong>“数字疾病”AI模型\u003C\u002Fstrong>为代表的 \u003Cstrong>\"生物芯片检测与人工智能分析\"技术体系\u003C\u002Fstrong>，实现\"\u003Cstrong>微量血+万项联检\u003C\u002Fstrong>\"的技术突破，让过去\"测不准、测不全、测不起\"的难题迎刃而解。\u003C\u002Fp>\r\n\u003Cp>此次立项，不仅是对碳云智能在\u003Cstrong>\"预测、预警、预防\"\u003C\u002Fstrong>领域核心攻关能力的高度肯定，更是对合作区支持自主创新硬科技、践行普惠健康使命的有力证明。碳云将持续深耕，让高价值的数字生命技术真正实现\u003Cstrong>\"社区可用、操作简便、人人可及\"\u003C\u002Fstrong>，使普惠筛查从理想走向日常，为推动我国生命科技产业化贡献碳云智慧。\u003C\u002Fp>","\u003Cp data-start=\"318\" data-end=\"681\">The project submitted by \u003Cstrong data-start=\"343\" data-end=\"355\">iCarbonX\u003C\u002Fstrong>, titled \u003Cstrong data-start=\"364\" data-end=\"523\">“High-Resolution Mapping of Protein Interaction Networks During Aging and Health-to-Disease Transition and Research on an Ultra-Early Risk Warning System,”\u003C\u002Fstrong> has been successfully selected for the \u003Cstrong data-start=\"563\" data-end=\"680\">2025 Industrial Core and Key Technology Research Program of the Hengqin Guangdong-Macao In-Depth Cooperation Zone\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"683\" data-end=\"985\">Focusing on protein interaction networks involved in aging and disease transition, the project aims to establish high-resolution interaction maps and develop an ultra-early risk warning system, representing a frontier exploration at the intersection of precision medicine and Digital Life technologies.\u003C\u002Fp>\r\n\u003Cp data-start=\"987\" data-end=\"1307\">The selection recognizes the innovation, feasibility, and strategic value of iCarbonX’s independently developed \u003Cstrong data-start=\"1099\" data-end=\"1190\">“globally exclusive next-generation silicon-based in situ synthesized bio-polymer chip”\u003C\u002Fstrong> and its application featuring \u003Cstrong data-start=\"1221\" data-end=\"1307\">“affordable testing, minimal blood samples, and thousands of simultaneous assays.”\u003C\u002Fstrong>\u003C\u002Fp>\r\n\u003Chr data-start=\"1309\" data-end=\"1312\">\r\n\u003Ch2 data-section-id=\"1s1x7i5\" data-start=\"1314\" data-end=\"1387\">Advancing Core Technologies to Address Strategic Healthcare Challenges\u003C\u002Fh2>\r\n\u003Cp data-start=\"1389\" data-end=\"1641\">The \u003Cstrong data-start=\"1393\" data-end=\"1505\">Industrial Core and Key Technology Research Program of the Hengqin Guangdong-Macao In-Depth Cooperation Zone\u003C\u002Fstrong> is a major industrial science and technology initiative focused on national strategic needs and breakthroughs in critical technologies.\u003C\u002Fp>\r\n\u003Cp data-start=\"1643\" data-end=\"1926\">Following multiple rounds of competitive evaluation, including eligibility review, expert assessment, centralized presentations, and on-site inspections, only \u003Cstrong data-start=\"1802\" data-end=\"1839\">16 projects were selected in 2025\u003C\u002Fstrong>, highlighting the program’s rigorous evaluation process and high level of recognition.\u003C\u002Fp>\r\n\u003Chr data-start=\"1928\" data-end=\"1931\">\r\n\u003Ch2 data-section-id=\"s52zs5\" data-start=\"1933\" data-end=\"2010\">Enabling High-Resolution Molecular Mapping of Aging and Disease Transition\u003C\u002Fh2>\r\n\u003Cp data-start=\"2012\" data-end=\"2240\">For decades, protein interaction networks involved in the transition from healthy aging to disease have remained a major technological challenge due to the lack of \u003Cstrong data-start=\"2176\" data-end=\"2239\">high-throughput and high-sensitivity detection technologies\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"2242\" data-end=\"2702\">Existing approaches face limitations including low throughput, high costs, large sample requirements, insufficient molecular identification depth, and dependence on imported core technologies. These challenges limit current diagnostic capabilities primarily to already-developed diseases, making it difficult to achieve accessible, efficient, high-resolution molecular mapping and ultra-early risk prediction models for aging and health-to-disease transitions.\u003C\u002Fp>\r\n\u003Chr data-start=\"2704\" data-end=\"2707\">\r\n\u003Ch2 data-section-id=\"7iuxp2\" data-start=\"2709\" data-end=\"2780\">Biochip Detection + AI Analysis Accelerating Digital Life Innovation\u003C\u002Fh2>\r\n\u003Cp data-start=\"2782\" data-end=\"3044\">Guided by its Digital Life vision, iCarbonX has developed an integrated technology system combining \u003Cstrong data-start=\"2882\" data-end=\"2940\">biochip detection and artificial intelligence analysis\u003C\u002Fstrong> through the convergence of semiconductor manufacturing processes and biological detection technologies.\u003C\u002Fp>\r\n\u003Cp data-start=\"3046\" data-end=\"3383\">Leveraging the \u003Cstrong data-start=\"3061\" data-end=\"3092\">iCTherapX™ Interaction Chip\u003C\u002Fstrong> and \u003Cstrong data-start=\"3097\" data-end=\"3126\">Digital Disease AI models\u003C\u002Fstrong>, iCarbonX has achieved breakthroughs in \u003Cstrong data-start=\"3167\" data-end=\"3238\">“minimal blood sample input with thousands of simultaneous assays,”\u003C\u002Fstrong> addressing long-standing challenges in molecular detection, including limited accuracy, insufficient detection coverage, and high testing costs.\u003C\u002Fp>\r\n\u003Cp data-start=\"3385\" data-end=\"3644\">The iCTherapX™ Interaction Chip enables high-throughput molecular interaction profiling through advanced silicon-based biochip technology, providing powerful support for applications in life science research, disease risk assessment, and precision healthcare.\u003C\u002Fp>\r\n\u003Chr data-start=\"3646\" data-end=\"3649\">\r\n\u003Ch2 data-section-id=\"kiubu5\" data-start=\"3651\" data-end=\"3702\">Making Digital Life Technologies More Accessible\u003C\u002Fh2>\r\n\u003Cp data-start=\"3704\" data-end=\"4026\">The approval of this project represents strong recognition of iCarbonX’s capabilities in advancing \u003Cstrong data-start=\"3803\" data-end=\"3848\">prediction, early warning, and prevention\u003C\u002Fstrong>, while also demonstrating the Hengqin Guangdong-Macao In-Depth Cooperation Zone’s support for independent innovation in advanced technologies and inclusive healthcare solutions.\u003C\u002Fp>\r\n\u003Cp data-start=\"4028\" data-end=\"4241\">Moving forward, iCarbonX will continue advancing Digital Life technologies, making high-value innovations more accessible through solutions that are \u003Cstrong data-start=\"4177\" data-end=\"4240\">community-ready, easy to operate, and available to everyone\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"4243\" data-end=\"4432\">By transforming inclusive health screening from a vision into everyday practice, iCarbonX aims to contribute innovative technologies and solutions to the industrialization of life sciences.\u003C\u002Fp>","640_4_1iwg4jp1dz.webp","mkwp708wgx8nlz6",true,"2026-04-11 18:00:00.000Z","zone-core-industrial-and-key-technology-r-d-project","近日，碳云智能申报的\"衰老及健康-疾病转化过程的高分辨率蛋白质互作组的图谱绘制及超早期风险预警体系研究\"项目，成功入选2025年度横琴粤澳深度合作区产业核心和关键技术攻关项目。","Recently, the project submitted by iCarbonX, titled “High-Resolution Mapping of Protein Interaction Networks During the Aging and Health-to-Disease Transition Process and Research on an Ultra-Early Risk Warning System,” was successfully selected for the 2025 Industrial Core and Key Technology Research Program of the Hengqin Guangdong-Macao In-Depth Cooperation Zone.","碳云智能成功入选2025年度横琴粤澳深度合作区产业核心和关键技术攻关项目","iCarbonX Successfully Selected for the 2025 Industrial Core and Key Technology Research Program of the Hengqin Guangdong-Macao In-Depth Cooperation Zone",0,{"category":198,"collectionId":199,"collectionName":200,"content":214,"content_en":215,"cover":216,"id":217,"published":205,"published_at":218,"slug":219,"summary":220,"summary_en":221,"title":222,"title_en":223,"views":212},"\u003Cp>近日，深圳碳云智肽药物科技有限公司（以下简称“碳云智肽”）与深圳翰宇药业股份有限公司（以下简称“翰宇药业”）正式达成股权投资合作，由翰宇药业增资碳云智肽，增资完成后其将正式成为碳云智肽股东，标志着双方将迈向更为深度的合作阶段。继前期成功研发协作后，双方关系全面升级，正式迈入资本与产业深度协同的新阶段，共同致力于推动AI驱动下的多肽创新药研发与产业化。  \u003Cbr>基于碳云智能的 InteraCtX 数字分子平台，碳云智肽已在AI药物发现领域构建起独特优势。此前，双方合作开发的GLP-1R\u002FGIPR\u002FGCGR 三重激动剂多肽创新药项目已验证了该平台的应用价值，为此次深度合作奠定了坚实基础。\u003Cbr>碳云智肽已构建起以硅基芯片+AI算法为核心的多肽药物设计平台，完成了商业模式的验证，形成了具有高度市场潜力的创新产品组合。碳云智肽技术平台的巨大潜力及创新产品价值是此次战略协同的核心。目前，公司主要管线包括：其一为已获得临床试验批准的抗菌肽iCAMP016，该药物基于多肽芯片与AI平台开发，具有结构新颖、广谱抗菌且对益生菌友好的特点；其二为靶向肿瘤微环境的多肽偶联药物（PDC）iCPDC-001，旨在实现针对实体瘤的精准递送，潜力巨大。\u003Cbr>翰宇药业作为多肽药物领域的领军企业，拥有覆盖研发、生产到商业化的完整产业链，具备行业领先的产业赋能实力。公司旗下武汉原料药生产基地、龙华研发中心均以“零缺陷”通过美国FDA检查，坪山制剂生产基地已获得中、美、欧等多国cGMP认证。基于国际一流的质量体系，翰宇药业构建了符合国际标准的CRDMO（Contract Research, Development, and Manufacturing Organization）一站式平台。依托该平台，未来将为碳云智肽的核心管线提供从工艺开发、临床生产到未来商业化供应的全周期支持。\u003Cbr>本次战略合作，标志着“前沿AI研发能力”与“成熟产业赋能体系”的有机融合。双方将共同应对多肽药物研发挑战，加速原创成果从实验室走向临床与市场，致力于为全球患者带来更多突破性的治疗方案。\u003C\u002Fp>","\u003Cp data-start=\"492\" data-end=\"765\">Recently, \u003Cstrong data-start=\"502\" data-end=\"529\">iCarbonX Pharmaceutical\u003C\u002Fstrong> and \u003Cstrong data-start=\"534\" data-end=\"551\">Hansoh Pharma\u003C\u002Fstrong> officially entered into an equity investment partnership. Through this agreement, Hansoh Pharma will make a capital investment in iCarbonX Pharmaceutical and become a shareholder upon completion of the investment.\u003C\u002Fp>\r\n\u003Cp data-start=\"767\" data-end=\"1116\">Following their successful collaboration in early-stage research and development, the partnership marks an upgrade from project-based cooperation to deeper integration of capital and industrial resources. Together, the two companies aim to accelerate the research, development, and commercialization of \u003Cstrong data-start=\"1070\" data-end=\"1115\">AI-driven innovative peptide therapeutics\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Chr data-start=\"1118\" data-end=\"1121\">\r\n\u003Ch2 data-section-id=\"1k3lsc9\" data-start=\"1123\" data-end=\"1218\">Advancing AI-Powered Peptide Drug Discovery Through the InteraCtX Digital Molecular Platform\u003C\u002Fh2>\r\n\u003Cp data-start=\"1220\" data-end=\"1393\">Powered by iCarbonX’s \u003Cstrong data-start=\"1242\" data-end=\"1282\">InteraCtX Digital Molecular Platform\u003C\u002Fstrong>, iCarbonX Pharmaceutical has established differentiated capabilities in the field of AI-driven drug discovery.\u003C\u002Fp>\r\n\u003Cp data-start=\"1395\" data-end=\"1630\">Previously, the two parties jointly developed a \u003Cstrong data-start=\"1443\" data-end=\"1510\">GLP-1R\u002FGIPR\u002FGCGR triple agonist peptide innovative drug program\u003C\u002Fstrong>, which validated the application potential of the platform and laid a strong foundation for this strategic partnership.\u003C\u002Fp>\r\n\u003Cp data-start=\"1632\" data-end=\"1870\">iCarbonX Pharmaceutical has developed a peptide drug design platform centered on \u003Cstrong data-start=\"1713\" data-end=\"1754\">silicon-based chips and AI algorithms\u003C\u002Fstrong>, completed business model validation, and established an innovative product portfolio with strong market potential.\u003C\u002Fp>\r\n\u003Cp data-start=\"1872\" data-end=\"2041\">The technological potential of iCarbonX Pharmaceutical’s platform and the value of its innovative pipeline represent the core foundation of this strategic collaboration.\u003C\u002Fp>\r\n\u003Chr data-start=\"2043\" data-end=\"2046\">\r\n\u003Ch2 data-section-id=\"erm1df\" data-start=\"2048\" data-end=\"2145\">Building an Innovative Peptide Drug Pipeline from Antimicrobial Peptides to Precision Oncology\u003C\u002Fh2>\r\n\u003Cp data-start=\"2147\" data-end=\"2206\">Currently, iCarbonX Pharmaceutical’s key pipelines include:\u003C\u002Fp>\r\n\u003Cp data-start=\"2208\" data-end=\"2493\">The first is \u003Cstrong data-start=\"2221\" data-end=\"2233\">iCAMP016\u003C\u002Fstrong>, an antimicrobial peptide drug candidate that has received clinical trial approval. Developed based on a \u003Cstrong data-start=\"2339\" data-end=\"2371\">peptide chip and AI platform\u003C\u002Fstrong>, iCAMP016 features a novel molecular structure, broad-spectrum antimicrobial activity, and a microbiome-friendly profile.\u003C\u002Fp>\r\n\u003Cp data-start=\"2495\" data-end=\"2704\">The second is \u003Cstrong data-start=\"2509\" data-end=\"2522\">iCPDC-001\u003C\u002Fstrong>, a \u003Cstrong data-start=\"2526\" data-end=\"2558\">peptide-drug conjugate (PDC)\u003C\u002Fstrong> targeting the tumor microenvironment, designed to enable precision delivery for solid tumors and demonstrating significant development potential.\u003C\u002Fp>\r\n\u003Chr data-start=\"2706\" data-end=\"2709\">\r\n\u003Ch2 data-section-id=\"w505pz\" data-start=\"2711\" data-end=\"2780\">Combining AI Innovation with Industrial Manufacturing Capabilities\u003C\u002Fh2>\r\n\u003Cp data-start=\"2782\" data-end=\"3050\">As a leading company in the peptide drug industry, \u003Cstrong data-start=\"2833\" data-end=\"2850\">Hansoh Pharma\u003C\u002Fstrong> has established a comprehensive industrial chain covering research and development, manufacturing, and commercialization, with strong capabilities in industrialization and pharmaceutical development.\u003C\u002Fp>\r\n\u003Cp data-start=\"3052\" data-end=\"3344\">Hansoh Pharma’s API manufacturing base in Wuhan and R&D center in Longhua successfully passed U.S. FDA inspections with \u003Cstrong data-start=\"3172\" data-end=\"3193\">zero deficiencies\u003C\u002Fstrong>, while its formulation manufacturing facility in Pingshan has obtained \u003Cstrong data-start=\"3265\" data-end=\"3288\">cGMP certifications\u003C\u002Fstrong> in China, the United States, Europe, and other regions.\u003C\u002Fp>\r\n\u003Cp data-start=\"3346\" data-end=\"3537\">Based on an internationally recognized quality management system, Hansoh Pharma has established a one-stop \u003Cstrong data-start=\"3453\" data-end=\"3527\">CRDMO (Contract Research, Development, and Manufacturing Organization)\u003C\u002Fstrong> platform.\u003C\u002Fp>\r\n\u003Cp data-start=\"3539\" data-end=\"3739\">Through this platform, Hansoh Pharma will provide comprehensive support for iCarbonX Pharmaceutical’s key pipelines, covering process development, clinical manufacturing, and future commercial supply.\u003C\u002Fp>\r\n\u003Chr data-start=\"3741\" data-end=\"3744\">\r\n\u003Ch2 data-section-id=\"1b1vd1g\" data-start=\"3746\" data-end=\"3834\">Accelerating the Translation of AI-Driven Peptide Innovations from Research to Market\u003C\u002Fh2>\r\n\u003Cp data-start=\"3836\" data-end=\"4008\">This strategic partnership represents the integration of \u003Cstrong data-start=\"3893\" data-end=\"3943\">advanced AI-driven drug discovery capabilities\u003C\u002Fstrong> with \u003Cstrong data-start=\"3949\" data-end=\"4007\">established pharmaceutical industrialization expertise\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"4010\" data-end=\"4299\">Together, the two companies will address key challenges in peptide drug development, accelerate the transition of innovative discoveries from laboratories to clinical applications and commercial markets, and strive to deliver more breakthrough therapeutic solutions for patients worldwide.\u003C\u002Fp>","e27a77e9_0e0f_4edb_b92e_8466b8378238_okgsxi6d5w.png","4yt91d4h1ab9lpy","2025-12-22 18:00:00.000Z","strategic-investment","近日，深圳碳云智肽药物科技有限公司（以下简称“碳云智肽”）与深圳翰宇药业股份有限公司（以下简称“翰宇药业”）正式达成股权投资合作，由翰宇药业增资碳云智肽，增资完成后其将正式成为碳云智肽股东，标志着双方将迈向更为深度的合作阶段。","Recently, Shenzhen iCarbonX Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “iCarbonX Pharmaceutical”) and Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as “Hanyu Pharmaceutical”) officially entered into an equity investment partnership. Through this agreement, Hanyu Pharmaceutical will make a capital increase investment in iCarbonX Pharmaceutical and will become a shareholder upon completion of the investment, marking the beginning of a deeper phase of collaboration between the two parties.","碳云智肽与翰宇药业达成战略投资合作，共筑AI多肽创新药新生","iCarbonX Pharmaceutical and Hansoh Pharma Establish Strategic Investment Partnership to Advance AI-Driven Peptide Drug Innovation",{"category":198,"collectionId":199,"collectionName":200,"content":225,"content_en":226,"cover":227,"id":228,"published":205,"published_at":229,"slug":230,"summary":231,"summary_en":232,"title":233,"title_en":234,"views":212},"\u003Cp>2025年12月17日，碳云智肽通过自主搭建的“AI技术+多肽芯片”融合平台研发的化学1类新药——抗菌肽iCAMP016阴道凝胶，正式获得国家药品监督管理局（NMPA）的临床试验批准，拟用于治疗细菌性阴道病。此前，公司已成功完成 GLP-1R\u002FGIPR\u002FGCGR 三重激动剂项目的对外授权（License-out）合作。iCAMP016 的 IND 获批，标志着公司创新药研发管线正式由临床前阶段迈入临床阶段，实现从技术验证到临床转化的关键跨越。\u003Cbr>\u003Cbr>AI驱动研发，突破传统局限\u003C\u002Fp>\r\n\u003Cp>iCAMP016是碳云智肽依托其核心AI算法与高通量多肽芯片InteraCtX™数字分子技术平台，经过高效筛选、合成与优化而得的创新成果。该项目获得深圳市科技重大专项支持（重202405018：基于 AI 技术联合多肽芯片平台的抗菌肽药物关键技术研发，项目编号：KJZD20240903103500002）。该药物通过靶向病原微生物细胞膜关键磷脂成分，快速破坏生物膜结构，实现高效杀菌。\u003C\u002Fp>\r\n\u003Cp>\u003Cbr>核心优势：精准抗菌与微生态友好\u003C\u002Fp>\r\n\u003Cp>临床前研究表明，iCAMP016能特异性靶向并快速破坏病原微生物的生物膜结构，对包括临床分离的加德纳菌、MRSA（耐甲氧西林金黄色葡萄球菌）、ESBLs大肠埃希菌及念珠菌在内的多种高威胁耐药菌与真菌均表现出强效、广谱的杀伤活性。\u003Cbr>其最具突破性的优势在于极高的选择性：在有效清除致病菌的同时，对维持阴道健康环境的关键益生菌（如卷曲乳杆菌）无抑制活性，从而有望在根治感染的同时，保护至关重要的微生态平衡，从源头上降低复发风险。\u003C\u002Fp>\r\n\u003Cp>药效与安全性双优，定位Best-in-Class在加德纳菌、MRSA、念珠菌等多种典型阴道感染动物模型中，iCAMP016均显著降低阴道病原菌载量，且呈现剂量依赖性疗效，优于部分现有阳性对照药物效。\u003Cbr>在安全性方面，该药物局部给药后系统暴露极低，无遗传毒性及明显刺激反应，其化学合成工艺成熟，稳定性高，具备优异的临床转化潜力。\u003C\u002Fp>\r\n\u003Cp>\u003Cbr>应对全球耐药挑战，开拓治疗新范式\u003C\u002Fp>\r\n\u003Cp>全球范围内，耐药菌感染已成为严峻的公共卫生挑战。碳云智肽通过AI驱动的抗菌肽开发平台，为多重耐药菌感染提供新型解决方案。iCAMP016作为局部用药，兼具广谱抗菌、不易诱导耐药、微生态保护三重优势，有望成为细菌性阴道病领域的突破性疗法。不仅为临床提供了潜在的全新治疗选择，也验证了其“数字分子”技术平台产出具有全球竞争力创新药的能力。\u003Cbr>碳云智肽表示，将严格按照国家法规要求，高质量推进iCAMP016的后续临床试验，并持续拓展抗菌肽在女性健康及其他感染性疾病领域的应用价值。后续将加速多条创新药管线的研发进程，致力于为患者带来更精准、更友好的新一代治疗方案。\u003C\u002Fp>","\u003Cp data-start=\"514\" data-end=\"940\">On December 17, 2025, \u003Cstrong data-start=\"536\" data-end=\"560\">iCAMP016 vaginal gel\u003C\u002Fstrong>, an antimicrobial peptide \u003Cstrong data-start=\"587\" data-end=\"624\">Class I innovative drug candidate\u003C\u002Fstrong> developed by \u003Cstrong data-start=\"638\" data-end=\"665\">iCarbonX Pharmaceutical\u003C\u002Fstrong> through its proprietary \u003Cstrong data-start=\"690\" data-end=\"744\">AI technology and peptide chip integrated platform\u003C\u002Fstrong>, officially received clinical trial approval from the \u003Cstrong data-start=\"799\" data-end=\"850\">National Medical Products Administration (NMPA)\u003C\u002Fstrong>. The drug candidate is being developed for the treatment of \u003Cstrong data-start=\"911\" data-end=\"939\">bacterial vaginosis (BV)\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"942\" data-end=\"1086\">Previously, the company successfully completed a \u003Cstrong data-start=\"991\" data-end=\"1020\">License-out collaboration\u003C\u002Fstrong> for its \u003Cstrong data-start=\"1029\" data-end=\"1085\">GLP-1R\u002FGIPR\u002FGCGR triple agonist peptide drug program\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"1088\" data-end=\"1349\">The IND approval of \u003Cstrong data-start=\"1108\" data-end=\"1120\">iCAMP016\u003C\u002Fstrong> marks the transition of iCarbonX Pharmaceutical’s innovative drug pipeline from the preclinical stage into clinical development, representing a key milestone in advancing its technologies from validation to clinical translation.\u003C\u002Fp>\r\n\u003Chr data-start=\"1351\" data-end=\"1354\">\r\n\u003Ch1 data-section-id=\"1y34lq0\" data-start=\"1356\" data-end=\"1421\">AI-Driven Drug Discovery Breaks Through Traditional Limitations\u003C\u002Fh1>\r\n\u003Cp data-start=\"1423\" data-end=\"1704\">iCAMP016 represents an innovative achievement developed by iCarbonX Pharmaceutical through its core AI algorithms and the \u003Cstrong data-start=\"1545\" data-end=\"1586\">InteraCtX™ Digital Molecular Platform\u003C\u002Fstrong>, integrating high-throughput peptide chip technology with efficient screening, synthesis, and optimization processes.\u003C\u002Fp>\r\n\u003Cp data-start=\"1706\" data-end=\"1972\">The program was supported by the \u003Cstrong data-start=\"1739\" data-end=\"1788\">Shenzhen Major Science and Technology Program\u003C\u002Fstrong>\u003Cbr data-start=\"1788\" data-end=\"1791\">(\u003Cstrong data-start=\"1792\" data-end=\"1970\">Project No. 202405018: Key Technology Development of Antimicrobial Peptide Drugs Based on AI Technology Combined with Peptide Chip Platform; Project No. KJZD20240903103500002\u003C\u002Fstrong>).\u003C\u002Fp>\r\n\u003Cp data-start=\"1974\" data-end=\"2134\">By targeting key phospholipid components of pathogen cell membranes, iCAMP016 rapidly disrupts biofilm structures and achieves effective antimicrobial activity.\u003C\u002Fp>\r\n\u003Chr data-start=\"2136\" data-end=\"2139\">\r\n\u003Ch1 data-section-id=\"1gguic5\" data-start=\"2141\" data-end=\"2228\">Core Advantages: Precision Antimicrobial Activity with Microbiome-Friendly Properties\u003C\u002Fh1>\r\n\u003Cp data-start=\"2230\" data-end=\"2622\">Preclinical studies demonstrated that \u003Cstrong data-start=\"2268\" data-end=\"2350\">iCAMP016 specifically targets and rapidly disrupts pathogen biofilm structures\u003C\u002Fstrong>, exhibiting potent and broad-spectrum activity against multiple high-risk drug-resistant bacteria and fungi, including clinically isolated \u003Cstrong data-start=\"2490\" data-end=\"2621\">Gardnerella vaginalis, MRSA (methicillin-resistant Staphylococcus aureus), ESBL-producing Escherichia coli, and Candida species\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"2624\" data-end=\"2898\">One of its most distinctive advantages lies in its high selectivity. While effectively eliminating pathogenic microorganisms, iCAMP016 demonstrates no inhibitory activity against key beneficial bacteria that contribute to vaginal health, such as \u003Cstrong data-start=\"2870\" data-end=\"2897\">Lactobacillus crispatus\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"2900\" data-end=\"3056\">This microbiome-friendly profile provides the potential to treat infections while preserving critical microbial balance and reducing the risk of recurrence.\u003C\u002Fp>\r\n\u003Chr data-start=\"3058\" data-end=\"3061\">\r\n\u003Ch1 data-section-id=\"1t3e4la\" data-start=\"3063\" data-end=\"3134\">Superior Efficacy and Safety Profile Supports Best-in-Class Potential\u003C\u002Fh1>\r\n\u003Cp data-start=\"3136\" data-end=\"3455\">In multiple animal models of vaginal infections involving \u003Cstrong data-start=\"3194\" data-end=\"3242\">Gardnerella vaginalis, MRSA, Candida species\u003C\u002Fstrong>, and other representative pathogens, iCAMP016 significantly reduced pathogen burden in vaginal tissues and demonstrated dose-dependent therapeutic effects, outperforming some existing positive control treatments.\u003C\u002Fp>\r\n\u003Cp data-start=\"3457\" data-end=\"3731\">In terms of safety, iCAMP016 shows extremely low systemic exposure following local administration, with no observed genotoxicity or significant irritation responses. Its chemical synthesis process is mature, with high stability and strong potential for clinical translation.\u003C\u002Fp>\r\n\u003Cp data-start=\"3733\" data-end=\"3852\">These characteristics support its potential positioning as a \u003Cstrong data-start=\"3794\" data-end=\"3851\">Best-in-Class antimicrobial peptide therapy candidate\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Chr data-start=\"3854\" data-end=\"3857\">\r\n\u003Ch1 data-section-id=\"r2t3vz\" data-start=\"3859\" data-end=\"3954\">Addressing Global Antimicrobial Resistance Challenges and Exploring New Therapeutic Paradigms\u003C\u002Fh1>\r\n\u003Cp data-start=\"3956\" data-end=\"4034\">Globally, antimicrobial resistance has become a major public health challenge.\u003C\u002Fp>\r\n\u003Cp data-start=\"4036\" data-end=\"4387\">Through its AI-driven antimicrobial peptide development platform, iCarbonX Pharmaceutical is developing innovative solutions for multidrug-resistant infections. As a locally administered therapy, iCAMP016 combines three key advantages: \u003Cstrong data-start=\"4272\" data-end=\"4386\">broad-spectrum antimicrobial activity, reduced potential for resistance development, and microbiome protection\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"4389\" data-end=\"4674\">The program has the potential to become a breakthrough therapeutic approach for bacterial vaginosis, providing a new treatment option for patients while further validating the capability of the \u003Cstrong data-start=\"4583\" data-end=\"4613\">Digital Molecular Platform\u003C\u002Fstrong> to generate globally competitive innovative drug candidates.\u003C\u002Fp>\r\n\u003Chr data-start=\"4676\" data-end=\"4679\">\r\n\u003Ch1 data-section-id=\"nnzrq0\" data-start=\"4681\" data-end=\"4760\">Advancing Innovative Drug Pipelines Toward More Precise Therapeutic Solutions\u003C\u002Fh1>\r\n\u003Cp data-start=\"4762\" data-end=\"4928\">iCarbonX Pharmaceutical stated that it will strictly follow regulatory requirements and continue advancing the clinical development of \u003Cstrong data-start=\"4897\" data-end=\"4909\">iCAMP016\u003C\u002Fstrong> with high quality.\u003C\u002Fp>\r\n\u003Cp data-start=\"4930\" data-end=\"5212\">The company will further explore the applications of antimicrobial peptides in women’s health and other infectious diseases, accelerate the development of multiple innovative drug pipelines, and strive to deliver more precise, patient-friendly next-generation therapeutic solutions.\u003C\u002Fp>","chat_gpt_image_2026_5_18_12_05_20_udr07vs0qx.png","bx65913oklz4r1a","2025-12-18 18:00:00.000Z","silicon-based-chip","2025年12月17日，碳云智肽通过自主搭建的“AI技术+多肽芯片”融合平台研发的化学1类新药——抗菌肽iCAMP016阴道凝胶，正式获得国家药品监督管理局（NMPA）的临床试验批准，拟用于治疗细菌性阴道病。此前，公司已成功完成 GLP-1R\u002FGIPR\u002FGCGR 三重激动剂项目的对外授权（License-out）合作。iCAMP016 的 IND 获批，标志着公司创新药研发管线正式由临床前阶段迈入临床阶段，实现从技术验证到临床转化的关键跨越。","On December 17, 2025, iCarbonX Pharmaceutical’s antimicrobial peptide drug candidate iCAMP016 vaginal gel, a Class I innovative drug developed through its proprietary AI technology and peptide chip integrated platform, officially received clinical trial approval from the National Medical Products Administration (NMPA). The drug candidate is being developed for the treatment of bacterial vaginosis (BV).\r\nPreviously, the company successfully completed a License-out collaboration for its GLP-1R\u002FGIPR\u002FGCGR triple agonist program. The IND approval of iCAMP016 marks the transition of iCarbonX Pharmaceutical’s innovative drug pipeline from the preclinical stage into clinical development, representing a key milestone in advancing its technologies from validation to clinical translation.","碳云智肽抗菌肽新药iCAMP016获临床试验批准，硅基芯片+AI 在制药领域火力全开","iCarbonX Pharmaceutical’s Antimicrobial Peptide Drug Candidate iCAMP016 Receives Clinical Trial Approval, Unleashing the Potential of Silicon-Based Chips + AI in Drug Discovery",{"category":198,"collectionId":199,"collectionName":200,"content":236,"content_en":237,"cover":238,"id":239,"published":205,"published_at":240,"slug":241,"summary":242,"summary_en":243,"title":244,"title_en":245,"views":212},"\u003Cp>近日，继十周年技术产品发布会后，碳云智能（iCarbonX）与澳大利亚头部公立医疗健康服务机构阿尔弗雷德健康集团（Alfred Health）和蒙纳士大学（Monash University）联合创立的澳大利亚人工智能健康中心（AI Health Institute, 下简称 AIHI），在珠海横琴粤澳合作中医药科技产业园正式签署战略合作框架协议。双方宣布，将基于AIHI的国家级临床人工智能平台与碳云智能的先进AI及多组学技术，共同加速精准医疗解决方案的研发与临床转化。\u003C\u002Fp>\r\n\u003Cp>\u003Cbr>签约仪式上，阿尔弗雷德健康放射学与核医学部主任、蒙纳士大学放射学教授 Prof Meng Law 与碳云智能创始人兼首席执行官王俊博士作为双方授权代表共同签署协议，并就双方合作发表重要致辞。双方就碳云发布的数字生命技术体系，含多组学硅基芯片及AI新药研发平台等前沿技术优势，结合澳大利亚人工智能健康中心丰富的医疗资源及临床需求，共同探索在精准医学、科研合作及新药研发等重要场景的创新落地。\u003Cbr>\u003Cbr>本次战略合作将重点聚焦以下领域：\u003Cbr>数字生命技术融合。联合开发AI算法，并整合碳云智能的数字检测及AI分析与AIHI的安全数据环境和MAVERIC超算。\u003Cbr>临床验证与评估。开展临床试验，利用高质量多组学数据评估AI工具在肿瘤等领域的效能。\u003Cbr>生态构建。共同制定数字生命与AI伦理治理框架，并开展人才培训与知识交流。\u003Cbr>此次合作标志着碳云智能的“数字生命”生态系统与国际顶尖临床科研资源实现深度对接。通过整合AIHI覆盖从场景数据、算力到临床验证的全链条平台能力，与碳云智能发布的硅基生物芯片系列及人工智能技术，双方旨在构建一个从数据洞察到临床落地的闭环，为AI在真实世界医疗场景中的应用树立新标杆。\u003Cbr>作为AI驱动生命科学领域的引领者，碳云智能始终秉持开放合作的态度，诚邀国内外临床、药企、健康、科研等各界伙伴携手，共同探索数字生命的无限未来。商务垂询，敬请联络：bd@icarbonx.com。\u003C\u002Fp>","\u003Cp data-start=\"438\" data-end=\"889\">Following its 10th Anniversary Technology and Product Launch Event, \u003Cstrong data-start=\"506\" data-end=\"518\">iCarbonX\u003C\u002Fstrong> has officially signed a strategic cooperation framework agreement with the \u003Cstrong data-start=\"594\" data-end=\"624\">AI Health Institute (AIHI)\u003C\u002Fstrong>, jointly established by \u003Cstrong data-start=\"649\" data-end=\"666\">Alfred Health\u003C\u002Fstrong>, a leading Australian public healthcare provider, and \u003Cstrong data-start=\"721\" data-end=\"742\">Monash University\u003C\u002Fstrong>. The signing ceremony took place at the \u003Cstrong data-start=\"783\" data-end=\"888\">Hengqin Guangdong-Macao Traditional Chinese Medicine Science and Technology Industrial Park in Zhuhai\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"891\" data-end=\"1145\">Through this partnership, both parties will leverage AIHI’s national clinical artificial intelligence platform and iCarbonX’s advanced AI and multi-omics technologies to accelerate the development and clinical translation of precision medicine solutions.\u003C\u002Fp>\r\n\u003Chr data-start=\"1147\" data-end=\"1150\">\r\n\u003Ch2 data-section-id=\"vg7mk1\" data-start=\"1152\" data-end=\"1239\">Combining Advanced Technologies and Clinical Resources to Advance Precision Medicine\u003C\u002Fh2>\r\n\u003Cp data-start=\"1241\" data-end=\"1564\">During the signing ceremony, \u003Cstrong data-start=\"1270\" data-end=\"1288\">Prof. Meng Law\u003C\u002Fstrong>, Head of Radiology and Nuclear Medicine at Alfred Health and Professor of Radiology at Monash University, and \u003Cstrong data-start=\"1399\" data-end=\"1415\">Dr. Jun Wang\u003C\u002Fstrong>, Founder and CEO of iCarbonX, signed the agreement as authorized representatives of both parties and delivered keynote remarks on the collaboration.\u003C\u002Fp>\r\n\u003Cp data-start=\"1566\" data-end=\"1953\">The two parties will explore innovative applications in key areas including precision medicine, scientific research collaboration, and drug discovery by combining iCarbonX’s \u003Cstrong data-start=\"1740\" data-end=\"1777\">Digital Life technology ecosystem\u003C\u002Fstrong>, including its multi-omics silicon-based biochip technologies and AI-driven drug discovery platforms, with AIHI’s extensive clinical resources and real-world healthcare needs.\u003C\u002Fp>\r\n\u003Chr data-start=\"1955\" data-end=\"1958\">\r\n\u003Ch2 data-section-id=\"1hmpuz4\" data-start=\"1960\" data-end=\"1989\">Key Areas of Collaboration\u003C\u002Fh2>\r\n\u003Ch3 data-section-id=\"1cv598i\" data-start=\"1991\" data-end=\"2030\">Digital Life Technology Integration\u003C\u002Fh3>\r\n\u003Cp data-start=\"2032\" data-end=\"2231\">The two parties will jointly develop AI algorithms and integrate iCarbonX’s digital detection and AI analysis capabilities with AIHI’s secure data environment and \u003Cstrong data-start=\"2195\" data-end=\"2230\">MAVERIC supercomputing platform\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Ch3 data-section-id=\"1s2fn33\" data-start=\"2233\" data-end=\"2271\">Clinical Validation and Evaluation\u003C\u002Fh3>\r\n\u003Cp data-start=\"2273\" data-end=\"2449\">The partnership will conduct clinical studies and utilize high-quality multi-omics datasets to evaluate the performance and effectiveness of AI tools in areas such as oncology.\u003C\u002Fp>\r\n\u003Ch3 data-section-id=\"1h4xl89\" data-start=\"2451\" data-end=\"2476\">Ecosystem Development\u003C\u002Fh3>\r\n\u003Cp data-start=\"2478\" data-end=\"2646\">Both parties will jointly establish frameworks for Digital Life and AI ethics governance, while promoting talent development, training programs, and knowledge exchange.\u003C\u002Fp>\r\n\u003Chr data-start=\"2648\" data-end=\"2651\">\r\n\u003Ch2 data-section-id=\"1bhp0aa\" data-start=\"2653\" data-end=\"2722\">Building a Closed Loop from Data Insights to Clinical Applications\u003C\u002Fh2>\r\n\u003Cp data-start=\"2724\" data-end=\"2876\">This strategic partnership marks the deep integration of iCarbonX’s \u003Cstrong data-start=\"2792\" data-end=\"2818\">Digital Life ecosystem\u003C\u002Fstrong> with internationally leading clinical research resources.\u003C\u002Fp>\r\n\u003Cp data-start=\"2878\" data-end=\"3212\">By combining AIHI’s comprehensive capabilities spanning real-world clinical data, computational infrastructure, and clinical validation with iCarbonX’s silicon-based biochip platforms and artificial intelligence technologies, the two parties aim to establish an integrated pathway from data-driven insights to clinical implementation.\u003C\u002Fp>\r\n\u003Cp data-start=\"3214\" data-end=\"3342\">This collaboration is expected to set a new benchmark for the application of AI technologies in real-world healthcare scenarios.\u003C\u002Fp>\r\n\u003Chr data-start=\"3344\" data-end=\"3347\">\r\n\u003Ch2 data-section-id=\"es2vu7\" data-start=\"3349\" data-end=\"3417\">Exploring the Future of Digital Life Through Global Collaboration\u003C\u002Fh2>\r\n\u003Cp data-start=\"3419\" data-end=\"3736\">As a leader in AI-driven life sciences, iCarbonX remains committed to open collaboration and innovation. The company welcomes partnerships with clinical institutions, pharmaceutical companies, healthcare organizations, and research communities worldwide to jointly explore the limitless possibilities of Digital Life.\u003C\u002Fp>\r\n\u003Cp data-start=\"3738\" data-end=\"3797\">For business inquiries, please contact: \u003Cstrong data-start=\"3778\" data-end=\"3797\">\u003Ca href=\"mailto:bd@icarbonx.com\" rel=\"noopener\" data-start=\"3780\" data-end=\"3795\">bd@icarbonx.com\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fp>","chat_gpt_image_2026_5_18_12_10_00_fyauhnnep9.png","5hf683054n5l54m","2025-11-30 18:00:00.000Z","strategic-cooperation","近日，继十周年技术产品发布会后，碳云智能（iCarbonX）与澳大利亚头部公立医疗健康服务机构阿尔弗雷德健康集团（Alfred Health）和蒙纳士大学（Monash University）联合创立的澳大利亚人工智能健康中心（AI Health Institute, 下简称 AIHI），在珠海横琴粤澳合作中医药科技产业园正式签署战略合作框架协议。双方宣布，将基于AIHI的国家级临床人工智能平台与碳云智能的先进AI及多组学技术，共同加速精准医疗解决方案的研发与临床转化。","Following iCarbonX’s 10th Anniversary Technology and Product Launch Event, iCarbonX and the AI Health Institute (AIHI), jointly established by Alfred Health, a leading Australian public healthcare provider, and Monash University, officially signed a strategic cooperation framework agreement at the Hengqin Guangdong-Macao Traditional Chinese Medicine Science and Technology Industrial Park in Zhuhai. Through this partnership, the two parties will leverage AIHI’s national clinical AI platform and iCarbonX’s advanced AI and multi-omics technologies to jointly accelerate the development and clinical translation of precision medicine solutions.","碳云智能与AIHI达成战略合作，共探AI与多组学融合新路径","iCarbonX and AIHI Establish Strategic Partnership to Explore New Frontiers in AI and Multi-Omics Integration",{"category":198,"collectionId":199,"collectionName":200,"content":247,"content_en":248,"cover":249,"id":250,"published":205,"published_at":251,"slug":252,"summary":253,"summary_en":254,"title":255,"title_en":256,"views":212},"\u003Cp>2026年5月8日，由碳云智肽申办的\"一项评估抗菌肽新药 iCAMP016 在健康成年女性志愿者中的安全性、耐受性和药代动力学特征的单中心、随机、双盲、单次给药剂量递增、安慰剂对照的 I 期临床研究\"启动会在天津医科大学总医院 I 期临床试验研究室顺利召开。此次启动会的召开，标志着碳云智肽抗菌肽新药 iCAMP016 正式进入临床研究实施阶段。iCAMP016 首发适应症为细菌性阴道病（Bacterial Vaginosis，BV), 碳云智肽后续还将围绕女性生殖道感染及微生态相关疾病持续推进该产品的临床开发与适应症拓展。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>\u003Cstrong>多方协同参与，保障临床研究规范开展\u003C\u002Fstrong>\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>本研究由\u003Cstrong>天津医科大学总医院\u003C\u002Fstrong>作为研究中心，I 期临床试验机构办主任朱晓冬教授、I 期临床试验机构办前任主任张庆瑜教授担任主要研究者。启动会现场，研究者宋学茹主任医师、赵书伟博士，以及给药、生物样本采集和处理、药品管理等 I 期临床试验机构相关团队成员共同参会。申办方碳云智肽、CRO 天津凯诺、SMO 天津汇诺医药相关项目团队同步参加会议。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>会上，各方围绕研究方案、研究药物、生物样本管理、知情同意书签署、GCP规范及项目实施关键环节进行了系统介绍和充分讨论，并就受试者权益保护、安全性观察、试验流程执行、样本采集处理、数据记录及质量控制等内容达成充分共识，为后续临床研究规范、有序开展奠定基础。\u003C\u002Fp>\r\n\u003Cp>\u003Cstrong>\u003Cbr>\u003C\u002Fstrong>\u003Cstrong>AI+多肽芯片赋能，推动抗菌肽新药临床转化\u003C\u002Fstrong>\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>iCAMP016 阴道凝胶是碳云智肽依托\"\u003Cstrong>AI技术+多肽芯片\u003C\u002Fstrong>\"融合平台研发的化学1类新药，已于2025年12月17日正式获得国家药品监督管理局（NMPA）临床试验批准，拟用于治疗细菌性阴道病。该项目进入\u003Cstrong>临床研究阶段\u003C\u002Fstrong>，是公司创新药研发管线从临床前研究迈向临床转化的重要里程碑。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>抗菌肽是一类具有抗微生物活性的功能性多肽，通常通过作用于病原微生物细胞膜等关键结构发挥抗菌作用。与传统抗生素相比，抗菌肽具有作用机制独特、开发潜力广泛等特点，在耐药菌感染、局部抗感染及微生态相关疾病治疗领域受到持续关注。根据临床前研究结果，\u003Cstrong>iCAMP016 可靶向病原微生物细胞膜关键磷脂成分，破坏生物膜结构，具有广谱优异的抗菌活性。\u003C\u002Fstrong>\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>同时，该药物在设计上关注阴道局部微生态环境，有望在清除致病菌的同时，尽可能减少对有益菌群的影响，为以细菌性阴道病为代表的女性生殖道感染及阴道微生态失衡相关疾病，探索更精准、更友好的潜在解决方案。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>\u003Cstrong>\u003Cbr>\u003C\u002Fstrong>\u003Cstrong>聚焦安全性与耐受性，持续布局女性健康领域\u003C\u002Fstrong>\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>本项 I 期临床研究拟在健康成年女性志愿者中开展，主要评价 iCAMP016 阴道凝胶单次给药后的安全性和耐受性，次要评价其药代动力学特征，并观察给药后阴道菌群及分泌物变化情况。研究采用单中心、随机、双盲、单次给药剂量递增、安慰剂对照设计，计划入组40例健康成年女性受试者。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>iCAMP016 阴道凝胶 I 期临床研究启动，是公司创新药研发管线推进的重要节点。公司将严格遵循国家药品监管要求和药物临床试验质量管理规范，与研究中心、CRO、SMO等合作伙伴密切协同，切实保障受试者权益与安全，高质量推进临床研究实施。\u003C\u002Fp>\r\n\u003Cp> \u003C\u002Fp>\r\n\u003Cp>未来，碳云智肽将继续依托硅基多肽芯片和数字分子AI平台，聚焦抗菌肽药物研发与临床转化，持续拓展其在女性健康及感染性疾病领域的应用价值，加速推进创新药管线研发进程，努力为患者带来更精准、更友好的新一代治疗方案。\u003C\u002Fp>","\u003Cp data-start=\"194\" data-end=\"480\">On May 8, 2026, the initiation meeting for the Phase I clinical study of \u003Cstrong data-start=\"267\" data-end=\"279\">iCAMP016\u003C\u002Fstrong>, an antimicrobial peptide drug candidate developed by \u003Cstrong data-start=\"334\" data-end=\"361\">iCarbonX Pharmaceutical\u003C\u002Fstrong>, was successfully held at the Phase I Clinical Trial Research Unit of \u003Cstrong data-start=\"432\" data-end=\"479\">Tianjin Medical University General Hospital\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"482\" data-end=\"795\">The study, titled \u003Cstrong data-start=\"500\" data-end=\"773\">“A Single-Center, Randomized, Double-Blind, Single-Dose Escalation, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of iCAMP016 Antimicrobial Peptide Drug Candidate in Healthy Adult Female Volunteers,”\u003C\u002Fstrong> officially commenced.\u003C\u002Fp>\r\n\u003Cp data-start=\"797\" data-end=\"1170\">The initiation of this study marks the transition of iCAMP016 into the clinical research stage. The first indication of iCAMP016 is \u003Cstrong data-start=\"929\" data-end=\"957\">Bacterial Vaginosis (BV)\u003C\u002Fstrong>. Going forward, iCarbonX Pharmaceutical will continue advancing the clinical development and indication expansion of this product, focusing on female reproductive tract infections and microbiome-related diseases.\u003C\u002Fp>\r\n\u003Chr data-start=\"1172\" data-end=\"1175\">\r\n\u003Ch2 data-section-id=\"ek7ges\" data-start=\"1177\" data-end=\"1266\">Multi-Party Collaboration Ensures the Standardized Implementation of Clinical Research\u003C\u002Fh2>\r\n\u003Cp data-start=\"1268\" data-end=\"1569\">The study is conducted at \u003Cstrong data-start=\"1294\" data-end=\"1341\">Tianjin Medical University General Hospital\u003C\u002Fstrong> as the clinical research center. Professor \u003Cstrong data-start=\"1385\" data-end=\"1401\">Xiaodong Zhu\u003C\u002Fstrong>, Director of the Phase I Clinical Trial Unit, and Professor \u003Cstrong data-start=\"1462\" data-end=\"1478\">Qingyu Zhang\u003C\u002Fstrong>, former Director of the Phase I Clinical Trial Unit, serve as the principal investigators.\u003C\u002Fp>\r\n\u003Cp data-start=\"1571\" data-end=\"1881\">The initiation meeting was attended by clinical researchers including \u003Cstrong data-start=\"1641\" data-end=\"1671\">Chief Physician Xueru Song\u003C\u002Fstrong> and \u003Cstrong data-start=\"1676\" data-end=\"1695\">Dr. Shuwei Zhao\u003C\u002Fstrong>, along with members of the Phase I clinical trial team responsible for drug administration, biological sample collection and processing, drug management, and other key study procedures.\u003C\u002Fp>\r\n\u003Cp data-start=\"1883\" data-end=\"2052\">Representatives from the sponsor \u003Cstrong data-start=\"1916\" data-end=\"1943\">iCarbonX Pharmaceutical\u003C\u002Fstrong>, CRO partner \u003Cstrong data-start=\"1957\" data-end=\"1974\">Tianjin Kaino\u003C\u002Fstrong>, and SMO partner \u003Cstrong data-start=\"1992\" data-end=\"2018\">Tianjin Huinuo Medical\u003C\u002Fstrong> also participated in the meeting.\u003C\u002Fp>\r\n\u003Cp data-start=\"2054\" data-end=\"2627\">During the meeting, all parties conducted in-depth discussions on key aspects of the clinical study, including the study protocol, investigational product management, biological sample management, informed consent procedures, GCP compliance, and project implementation. Consensus was reached on critical areas including participant safety and rights protection, safety monitoring, trial process execution, sample collection and handling, data recording, and quality control, laying a solid foundation for the standardized and efficient implementation of the clinical study.\u003C\u002Fp>\r\n\u003Chr data-start=\"2629\" data-end=\"2632\">\r\n\u003Ch2 data-section-id=\"18b9rhr\" data-start=\"2634\" data-end=\"2716\">AI + Peptide Chip Technology Accelerates Antimicrobial Peptide Drug Translation\u003C\u002Fh2>\r\n\u003Cp data-start=\"2718\" data-end=\"3093\">\u003Cstrong data-start=\"2718\" data-end=\"2742\">iCAMP016 vaginal gel\u003C\u002Fstrong> is a \u003Cstrong data-start=\"2748\" data-end=\"2785\">Class I innovative drug candidate\u003C\u002Fstrong> developed by \u003Cstrong data-start=\"2799\" data-end=\"2826\">iCarbonX Pharmaceutical\u003C\u002Fstrong> based on the integration of \u003Cstrong data-start=\"2855\" data-end=\"2899\">AI technology and peptide chip platforms\u003C\u002Fstrong>. The program received clinical trial approval from the \u003Cstrong data-start=\"2955\" data-end=\"3006\">National Medical Products Administration (NMPA)\u003C\u002Fstrong> on December 17, 2025, and is being developed for the treatment of bacterial vaginosis.\u003C\u002Fp>\r\n\u003Cp data-start=\"3095\" data-end=\"3239\">The initiation of clinical research represents an important milestone as iCAMP016 advances from preclinical studies toward clinical translation.\u003C\u002Fp>\r\n\u003Cp data-start=\"3241\" data-end=\"3711\">Antimicrobial peptides are a class of functional peptides with antimicrobial activity. They typically exert their effects by targeting key structures of microorganisms, such as cell membranes. Compared with traditional antibiotics, antimicrobial peptides feature unique mechanisms of action and broad development potential, attracting increasing attention in areas including drug-resistant infections, localized anti-infective therapies, and microbiome-related diseases.\u003C\u002Fp>\r\n\u003Cp data-start=\"3713\" data-end=\"3917\">According to preclinical research results, \u003Cstrong data-start=\"3756\" data-end=\"3917\">iCAMP016 targets key phospholipid components of pathogen cell membranes, disrupts biofilm structures, and demonstrates broad-spectrum antimicrobial activity.\u003C\u002Fstrong>\u003C\u002Fp>\r\n\u003Cp data-start=\"3919\" data-end=\"4370\">The design of iCAMP016 also considers the local vaginal microbiome environment, aiming to eliminate pathogenic microorganisms while minimizing potential disruption to beneficial microbial communities. This approach provides a potential new solution for female reproductive tract infections and microbiome imbalance-related diseases, including bacterial vaginosis, with the goal of achieving more precise and microbiome-friendly therapeutic strategies.\u003C\u002Fp>\r\n\u003Chr data-start=\"4372\" data-end=\"4375\">\r\n\u003Ch2 data-section-id=\"17l7rgp\" data-start=\"4377\" data-end=\"4448\">Advancing Women’s Health Through Safety-Focused Clinical Development\u003C\u002Fh2>\r\n\u003Cp data-start=\"4450\" data-end=\"4820\">This Phase I clinical study will be conducted in healthy adult female volunteers. The primary objective is to evaluate the \u003Cstrong data-start=\"4573\" data-end=\"4600\">safety and tolerability\u003C\u002Fstrong> of iCAMP016 vaginal gel following a single administration. Secondary objectives include evaluating its \u003Cstrong data-start=\"4704\" data-end=\"4739\">pharmacokinetic characteristics\u003C\u002Fstrong> and observing changes in vaginal microbiota and secretions after administration.\u003C\u002Fp>\r\n\u003Cp data-start=\"4822\" data-end=\"5007\">The study adopts a \u003Cstrong data-start=\"4841\" data-end=\"4935\">single-center, randomized, double-blind, single-dose escalation, placebo-controlled design\u003C\u002Fstrong>, with a planned enrollment of \u003Cstrong data-start=\"4966\" data-end=\"5006\">40 healthy adult female participants\u003C\u002Fstrong>.\u003C\u002Fp>\r\n\u003Cp data-start=\"5009\" data-end=\"5474\">The initiation of the Phase I clinical study of \u003Cstrong data-start=\"5057\" data-end=\"5081\">iCAMP016 vaginal gel\u003C\u002Fstrong> represents a significant milestone in the advancement of iCarbonX Pharmaceutical’s innovative drug pipeline. The company will strictly follow national regulatory requirements and Good Clinical Practice (GCP) guidelines, working closely with clinical research centers, CROs, SMOs, and other partners to ensure participant safety and rights while advancing the clinical study with high quality.\u003C\u002Fp>\r\n\u003Cp data-start=\"5476\" data-end=\"5910\">Looking ahead, \u003Cstrong data-start=\"5491\" data-end=\"5518\">iCarbonX Pharmaceutical\u003C\u002Fstrong> will continue leveraging its \u003Cstrong data-start=\"5548\" data-end=\"5623\">silicon-based peptide chip technology and Digital Molecular AI platform\u003C\u002Fstrong> to advance antimicrobial peptide drug discovery and clinical translation. By expanding applications in women’s health and infectious diseases, the company aims to accelerate innovative drug development and deliver more precise and patient-friendly next-generation therapeutic solutions.\u003C\u002Fp>","chat_gpt_image_2026_5_9_10_47_34_2_eh8iaxdw74.png","dr692h33o4egqg6","2024-05-09 00:00:00.000Z","icarbonx-pharmaceutical-initiates-phase-i-clinical-study-of-icamp016","未来，碳云智肽将继续依托硅基多肽芯片和数字分子AI平台，聚焦抗菌肽药物研发与临床转化，持续拓展其在女性健康及感染性疾病领域的应用价值，加速推进创新药管线研发进程，努力为患者带来更精准、更友好的新一代治疗方案。","Going forward, iCarbonX Pharmaceutical will continue leveraging its silicon-based peptide chip technology and Digital Molecular AI platform to advance antimicrobial peptide drug discovery and clinical translation, expand the applications of its technologies in women’s health and infectious diseases, accelerate the development of innovative drug pipelines, and strive to deliver more precise and patient-friendly next-generation therapeutic solutions.","碳云智肽抗菌肽新药 iCAMP016 I 期临床研究正式启动","iCarbonX Pharmaceutical Initiates Phase I Clinical Study of Antimicrobial Peptide Drug Candidate iCAMP016"]